Tilray Sees Cannabis Rescheduling as Gateway to U.S. Medical Market
Tilray Brands believes it can get into the medical marijuana business in the U.S. pretty quickly if the Biden administration reclassifies cannabis as a Schedule 3 drug sometime this year, CEO Irwin S…